A healthy-looking adult smiling warmly in a natural outdoor setting
UK Clinical Study

Living with immune thrombocytopenia (ITP)?

Many people living with immune thrombocytopenia (ITP) may not experience noticeable symptoms, even when platelet counts are low.

This UK clinical study is evaluating an investigational treatment for adults with ITP.

People who take part in the study may receive compensation for their time and inconvenience, as well as reimbursement for reasonable travel expenses.

All participants enrolled in the study will receive the investigational medicine. There is no placebo group in this study.

6
Night residential stay
11
Outpatient visits
1
Follow-up call
Call the Study Team

Why people look into studies like this

People explore clinical studies for different reasons.

Stay informed

Some people with ITP want to understand new treatment research before they need another option.

Helping others & advancing science

Participating helps researchers learn more about potential future therapies.

Reimbursement and compensation

Participants may receive compensation for time and inconvenience, and reimbursement for travel expenses.

Clinical monitoring

Trials offer close monitoring by doctors and nurses with expertise in conducting clinical trials.

A simple first step is a short telephone call to assess whether the study may be suitable.

Common questions

Many people with ITP feel well even when platelet counts are low. Some choose to learn about research so they understand potential future treatment options.

No. All participants receive the investigational medication.

After successful screening, the study involves 48 days of active participation, including a six-night residential stay and outpatient visits. A follow-up phone call takes place one week later.

Participants may receive compensation for their time and inconvenience and may be reimbursed for reasonable travel expenses.

The study team will explain screening results and next steps.

You do not need to know your exact platelet count. Platelet levels are assessed by the study team during the screening process.

Study locations in the United Kingdom

This study is being conducted at specialized research units in the UK, including in Leeds and Nottingham, with other sites expected to open soon. The study team can help determine which location may be most convenient.

UK Research Locations

Leeds, Nottingham, and additional sites opening soon.

Call 0113 394 5200

Interested in learning more?

If you have ITP and want to find out whether this study may be suitable, the study team can walk you through the next step.

Call the Study Team

Phone: 0113 394 5200

Study Reference: 780567

Understanding ITP

Immune thrombocytopenia (ITP) can affect people differently

Immune thrombocytopenia, or ITP, is a condition that causes low platelet counts.

Platelets help blood clot and help control bleeding.

One unusual aspect of ITP is that many people may feel well even when platelet levels are low. Some people discover they have ITP through routine blood tests rather than symptoms.

Because symptoms and platelet levels do not always match, research continues to explore new approaches for managing ITP.

Microscopic illustration of activated platelets in the bloodstream

Red blood cells, activated platelets (with bulges), and white blood cells

Resources for people with ITP

These external resources provide additional information about ITP diagnosis, treatment, and patient support in the United Kingdom.

ITP Support Association (UK)
Information, support, and community for people living with ITP in the UK.
UK Centres of Excellence in ITP treatment
Specialist centres across the UK with expertise in managing ITP.
Information on ITP from the ITP Support Association
Learn about ITP causes, symptoms, diagnosis, and treatment options.

Interested in the GL-2045 study?

About the Study

About the GL-2045 ITP Study

This study is evaluating an investigational drug known as GL-2045 which is being tested for safety and efficacy in people with Immune Thrombocytopenia (ITP) who have had a good prior platelet count response to either steroids or IVIg (Intravenous Immune Globulin).

GL-2045 is a cell-grown biologic (similar to many approved products) that has been designed to mimic the active component of IVIg which is a blood product pooled from thousands of donors and used to treat patients with ITP.

Dosing is injections under the skin (subcutaneous, SC). In nearly 50 healthy people who have received GL-2045 SC injections, the drug has been safe and well tolerated. This is the first study in patients.

Potential benefits of GL-2045 compared to IVIG are expected to include smaller and more convenient dosing and avoidance of human blood derived drug like IVIG.

More information on GL-2045

What participation looks like

1
Screening visit
Medical history and assessments are reviewed to check whether you may be eligible.
2
Residential stay
Participants stay at the research clinic for approximately six nights while receiving study medication and monitoring.
3
Outpatient visits
Participants return for follow-up clinic visits over several weeks.
4
Final follow-up
The study includes a final follow-up telephone call.

Could you qualify?

Whether you may be able to take part in the study depends on your medical history and whether you meet the study criteria. Not everyone will be eligible to take part. The study team will review this information to help decide whether participation would be appropriate and safe for you.

Main requirements

There are quite a few criteria that determine eligibility to participate. Your past medical history and medications will affect eligibility. Here are four key requirements:

Patient in a clinical setting speaking with a doctor during a consultation
Age 18 to 80
Diagnosed immune thrombocytopenia (ITP)
A platelet count within a range required by the study, assessed during screening
A documented previous response to treatment with corticosteroids or IVIg

Some people may not qualify if they have had

Recent splenectomy
Recent bleeding events
Certain thromboembolic events
Recent ITP medications or blood products

What researchers are studying

Safety

Researchers assess the safety and tolerability of the study medication.

Platelet response

Changes in platelet counts are measured.

Body response

Researchers examine how the body processes the medication.

All participants in this study will receive the investigational medication.

Study oversight

Participants are monitored by the study team at the clinical trial site. Monitoring includes blood tests, physical examinations, vital signs, ECGs, and other study related assessments.

Participation

What participation involves

Here are the steps involved in the study.

Study timeline

1
Screening visit
Medical history review and screening assessments are carried out to check whether you may be eligible to take part.
2
Residential stay (Day 0 to Day 6)
Participants attend a planned stay of approximately six nights at a clinical research unit, starting on Day 0 and ending on Day 6.
3
Outpatient visits (approximately Day 7 to Day 36)
For around three weeks after the residential stay, participants attend scheduled outpatient visits, during which the study medication may be given. Dosing is planned to finish by around Day 25, followed by a small number of further visits for observation and study assessments.
4
Follow-up visit (around Day 48)
Participants attend an out-patient follow-up assessment at around Day 48.
5
Phone check-in (around Day 55)
A final follow-up phone call is planned at around Day 55.

Study activities

Blood tests
Physical exams
ECG monitoring
Vital signs
Questionnaires
Study medication dosing

Participants may receive compensation for time and inconvenience. Reasonable travel costs may be reimbursed.

Get in Touch

Interested in participating?

Contact the study team to discuss whether taking part in this clinical study may be suitable for you.

0113 394 5200
Study Reference: 780567
Call the Study Team

What happens next

1
Initial conversation
Have an initial conversation with the study team to find out more about the study and review your medical history.
2
Eligibility screening
A phone pre-screening discussion to check whether you may meet the study criteria.
3
Screening visit (if appropriate)
An in-person visit at a Fortrea clinical research unit to further assess eligibility.

Referral information

For patients

Patients may contact the study team directly by calling the number above.

For clinicians

Clinicians may refer patients with consent for screening.

Privacy Policy

Effective Date: 24 March 2026 | Last Updated: 24 March 2026

1. Introduction

Gliknik Inc. ("Company," "we," "us," or "our") operates this website ITPtrial.com (the "Site") to provide general information about an ongoing clinical research study for certain types of eligible ITP patients.

We are committed to protecting your privacy and aligning our practices with applicable regulatory expectations for clinical research communications, including those of health authorities such as the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

2. Purpose of the Site

This Site is intended solely for informational purposes. It does not enroll participants into clinical trials, conduct eligibility screening, or collect personal or health information.

All clinical trial-related activities, including screening, informed consent, and data collection, are conducted by clinical investigators and their designated representatives who are authorized by applicable regulatory agencies.

3. No Collection of Personal Data

We have designed this Site to avoid the collection of personal data. We do not request, collect, or store personally identifiable information (such as name, email address, phone number, or address). We do not collect or process health-related or sensitive personal data. Users are instructed not to submit personal or medical information through this Site.

If you choose to follow links to external sites, any information you provide will be governed by those third parties' privacy policies.

4. Limited Technical Data Collection

We may automatically collect limited technical data necessary to operate and secure the Site, such as IP address, browser type and version, device type, pages visited and timestamps. This information is used only for site functionality, security, and aggregated analytics, is not used to identify individuals, and is processed in a manner consistent with applicable data protection principles (e.g., data minimization and purpose limitation).

5. Cookies and Analytics

We may use cookies or similar technologies that are strictly necessary for basic website functionality, performance monitoring, and aggregated usage analytics. Where applicable, cookie use will be limited to non-intrusive technologies, and users may control cookie settings through their browser.

6. External Links and Third Parties

The Site may contain links to third-party websites, including clinical trial sites or service providers. These third parties operate independently and may collect personal and health information. Such data collection is governed by their own privacy notices and regulatory obligations. We do not control and are not responsible for third-party privacy practices.

7. Data Sharing

Because we do not collect personal data, we do not sell, share, or disclose personal information. We may use service providers (e.g., hosting or analytics providers) that process limited technical data on our behalf under appropriate contractual safeguards.

8. Data Security

We implement appropriate technical and organizational measures to protect the integrity and security of the Site and the limited data processed in connection with it.

9. Regulatory Position

This Site is not intended to replace informed consent processes, serve as a platform for collection of clinical trial data, or function as a clinical database or patient registry. All personal and clinical data relevant to participation in any study are collected and managed exclusively by authorized clinical sites in accordance with applicable regulations and guidelines, including Good Clinical Practice (GCP).

10. Children's Privacy

This Site is not intended for individuals under the age of 18, and we do not knowingly collect information from children.

11. Your Rights

Because we do not collect personal data through this Site, we are generally not in a position to access, correct, or delete personal information about you. If you provide information to a third-party clinical site, you should contact that organization directly to exercise any applicable rights.

12. Changes to This Privacy Policy

We may update this Privacy Policy from time to time. Any updates will be reflected by the "Last Updated" date at the top of this page.

13. Contact Us

If you have questions about this Privacy Policy, please contact:

Gliknik Inc.
801 W. Baltimore Street
Baltimore, MD 21201

Cookie Policy

Effective Date: 24 March 2026 | Last Updated: 24 March 2026

1. Introduction

This Cookie Policy explains how Gliknik Inc. ("Company," "we," "us," or "our") uses cookies and similar technologies on ITPtrial.com (the "Site"). This Site is designed to minimize data collection and does not intentionally collect personal or health information.

2. What Are Cookies

Cookies are small text files that are placed on your device when you visit a website. They help websites function properly and provide information about how the site is used.

3. Types of Cookies We Use

a. Strictly Necessary Cookies
These cookies are essential for the operation, security, and integrity of the Site. They do not require user consent and do not store personally identifiable information.

b. Limited Analytics Cookies
We may use limited analytics tools (such as Google Analytics or similar technologies) to understand how visitors use the Site. These cookies collect aggregated and de-identified information, such as pages visited, time spent on the Site, and general geographic region (e.g., country-level). We configure such tools, where feasible, to minimize data collection, avoid collection of directly identifying information, and support IP anonymization or equivalent measures. These cookies are used to improve site performance and usability.

4. Third-Party Cookies

Analytics services may set cookies on our behalf. These providers process data in accordance with their own privacy policies and applicable legal requirements. We do not use cookies for advertising, behavioral profiling, or cross-site tracking.

5. Data Protection Approach

Consistent with our overall privacy approach, we do not seek to identify individual users, we do not combine analytics data with other datasets, and we do not use cookies to collect health or sensitive personal data.

6. Managing Cookies

Most web browsers allow you to control cookies through their settings. You can block cookies, accept or reject non-essential cookies via any cookie banner or settings presented on the Site, delete existing cookies, and set preferences for certain websites. Please note that disabling strictly necessary cookies may affect Site functionality.

7. Changes to This Cookie Policy

We may update this Cookie Policy from time to time. Updates will be reflected by the "Last Updated" date above.

8. Contact Us

If you have questions about this Cookie Policy, please contact:

Gliknik Inc.
801 W. Baltimore Street
Baltimore, MD 21201

Accessibility Statement

Effective Date: 24 March 2026 | Last Updated: 24 March 2026

Gliknik Inc. is committed to ensuring that this website is accessible to all users, including individuals with disabilities.

We aim to design and maintain this Site in alignment with generally recognized accessibility standards, including the Web Content Accessibility Guidelines (WCAG) 2.1 Level AA, to support usability with assistive technologies such as screen readers and keyboard navigation.

Because this Site is informational in nature and does not collect personal or health information, we have focused on implementing core accessibility features, including clear page structure and navigation, readable text with sufficient color contrast, alternative text for images, and keyboard-accessible functionality.

We recognize that accessibility is an ongoing process and are continually working to improve the user experience for all visitors. We want to know if you experience any difficulty accessing content on this Site or have suggestions for improving accessibility. Please contact us:

Gliknik Inc.
801 W. Baltimore Street
Baltimore, MD 21201

We will make reasonable efforts to address accessibility issues in a timely manner.

Disclaimer: This statement reflects our current accessibility practices and ongoing commitment to improving accessibility.